

CHANGE OF DIRECTOR'S INTERESTS

Attached is an Appendix 3Y Notice for Mr David Brookes which is in relation to the acquisition by Mr Brookes of an interest in 2,500,000 shares on 8 October 2021 pursuant to the public offering conducted by the Company to raise \$4 million.

The intention of Mr Brookes to acquire an interest in these shares was disclosed at page 92 of the Replacement Prospectus dated 9 September 2021, however due to an administrative oversight, an Appendix 3Y relating to the acquisition of those shares was not lodged.

The Company has reviewed its procedures to ensure such an oversight does not re-occur.

This announcement has been authorised by the Company Secretary.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS)
ABN	45 101 955 088

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Brookes
Date of last notice	27 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr. D. L. Brookes Personal Superannuation Fund (of which Dr Brookes is a beneficiary) Dahlbrook Family Trust (of which Dr Brookes is appointer of the Trust)
Date of change	8 October 2021
No. of securities held prior to change	500,000 unlisted share options 2,401,250 fully paid ordinary shares
Number acquired	2,500,000 fully paid ordinary shares
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per share
No. of securities held after change	500,000 unlisted share options 4,901,250 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired at \$0.04 per share pursuant to the Public Offer described in the Replacement Prospectus dated 9 September 2021.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.